Background Randomized clinical trials have defined the survival advantage with the
addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer …

Background Biologic agents have improved the outcomes of patients with metastatic
colorectal cancer (mCRC). However, the clinical trials included a predominately white …

Importance Randomized clinical trials have defined the survival benefit provided by the
addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer …

Purpose: With the emergence of new chemotherapies and biologic agents in the treatment
of metastatic colorectal cancer (mCRC), the optimal combination and sequencing of these …

4100 Background: The relationship between race and clinical outcomes with systemic
chemotherapy in patients with metastatic colorectal cancer is uncertain. E3200 is a large …

Abstract Background In United States Hispanics have disparities in the presentation and
outcome of colorectal cancer (CRC) largely attributed to their late presentation and lower …

Background Over the last decade, multiple chemotherapies/targeted biologics have been
approved for metastatic colorectal cancer (mCRC). However, evidence is limited with …

Aim A s multiple new agents have been added to the treatment options for patients with
metastatic colorectal cancer, survival outcomes in clinical trials have continued to improve …

3537 Background: Few population studies have examined treatment regimens and duration
in mCRC since the introduction of biologic therapies in 2004. Methods: We assessed 4,877 …

Background Since the introduction of biologic therapies for the treatment of metastatic
colorectal cancer (mCRC), few studies have examined patterns of care or predictors of …